Prognostic value of the short-term antiproteinuric response to ACE inhibition for prediction of GFR decline in patients with nondiabetic renal disease

Experimental Nephrology

Volumn 4, Issue SUPPL. 1, 1996, Pages 47-52

  Wapstra, Frits H ^a   Navis, Gerjan ^a   De Jong, Paul E ^a   De Zeeuw, Dick ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

ACE inhibition; Antiproteinuric treatment; Chronic renal failure; Prevention; Proteinuria

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL;

CHRONIC KIDNEY FAILURE; GLOMERULUS FILTRATION RATE; HUMAN; PRIORITY JOURNAL; PROTEINURIA; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; PROGNOSIS; PROTEINURIA;

EID: 0029731148     PISSN: 10187782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Ellis A: Natural history of Blight's disease; clinical, histological and experimental observations. The vicious circle in Bright's disease. Lancet 1942;i:72-76.
2. Mitch WE, Buffington G, Lemann J, Walser M: Progression of renal failure: A simple method of estimation. Lancet 1976;ii:1326-1331.
3. Klahr S, Schreiner G, Ichikawa I: The progression of renal disease. N Engl J Med 1988;318: 1657-1666.
4. Alvestrand A, Gutierrez A, Bucht H, Bergström J: Reduction of blood pressure retards the progression of chronic renal failure in man. Nephrol Dial Transplant 1988;3:624-631.
5. Brenner BM, Meyer TW, Hostetter TW: Dietary protein and the progressive nature of kidney disease: Role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis of aging, renal ablation and intrinsic renal disease. N Engl J Med 1982;307:652-659.
6. Williams PS, Fass G, Bone JM: Renal pathology and proteinuria determine progression in untreated mild/moderate chronic renal failure. Q J Med 1988;67:343-354.
7. Keane WF, Kasiske B, O'Donnell MP, Kin Y: The role of altered lipid metabolism in the progression of renal disease. Am J Kidney Dis 1991;17:S38-S42.
8. Remuzzi G, Bertani T: Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? (editorial). Kidney Int 1990;38:384-394.
9. Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D: Reduction of proteinuria by angiotensin-converting enzyme inhibition. Kidney Int 1987;32:78-83.
10. Gansevoort RT, de Zeeuw D, Shahinfar S, Redfield A, de Jong PE: Effects of the angiotensin-II receptor antagonist Losartan in hypertensive patients with renal disease. J Hypertens 1994;12:S37-S42.
11. Ahlem J: Incidence of human chronic renal insuffiency. A study of the incidence and pattern of renal insufficiency in adults during 1966-71 in Gothenburg. Acta Med Scand 1975;suppl 582:1-50.
12. Hannedouche T, Chaveur P, Fehrat A, Alboouze G, Jungers P: Effect of moderate protein restriction on the rate of progression of chronic renal failure. Kidney Int 1989;36:S91-S95.
13. Williams PS, Fass G, Bone JM: Renal pathology and proteinuria determine progression in untreated mild/moderate chronic renal failure. Q J Med 1988;67:343-354.
14. Bergström J, Alvestrand A, Bucht H, Gutierrez A, Stenvinkel P: Is chronic renal failure always progressive?. The Progressive Nature of Renal Disease: Myths and Facts. Contrib Nephrol. Basel, Karger, 1989, vol 75, pp 60-67.
15. Locatelli F, Marcelli D, Comelli M, Alberti D, Graziani G, Buccianti G, Redaelli B, Giangrande A, and the Northern Italian Cooperative Study Group: Proteinuria and blood pressure as causal components of progression to end-stage renal failure. Nephrol Dial Transplant 1996;11:461-467.
16. Wight JP, Salzano S, Brown CB, El Nahas AM: Natural history of chronic renal failure: A reappraisal. Nephrol Dial Transplant 1992;7:379-383.
17. Kincaid-Smith P, Becker G: Reflux nephropathy and chronic atrophic pyelonephritis: A review. J Infect Dis 1978;138:174-180.
18. El Khatib MT, Becker GJ, Kancaid-Smith PS: Morphometric aspects of reflux nephropathy. Kidney Int 1987;32:261-266.
19. Stenvinkel P, Alvestrand A, Bergström J: Factors influencing progression in patients with chronic renal failure. J Intern Med 1989;226: 183-188.
20. Brazy PC, Fitzwilliam JF: Progressive renal disease: Role of race and antihypertensive medications. Kidney Int 1990;37:1113-1119.
21. Apperloo AJ, de Zeeuw D, de Jong PE: Short-term antiproteinuric response to antihypertensive therapy predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int 1994;45(suppl 45):S174-S178.
22. Kamper A-L, Strandgaard S, Leyssac S, Leyssac PP: Late outcome of a controlled trial of enalapril treatment in progressive chronic renal failure. Hard end-points and influence of proteinuria. Nephrol Dial Transplant 1995;10: 1182-1188.
23. Smith SR, Svetket LP, Dennis VW: Racial differences in renal disease. Kidney Int 1991;41: 815-822.
24. van Essen GG, Rensma PL, de Zeeuw D, Sluiter WJ, Scheffer H, Aperloo AJ, de Jong PE: Association between angiotensin-converting enzyme gene polymorphism and failure of renoprotective therapy. Lancet 1996;347:94-95.
25. 131I-hippuran. J Am Soc Nephrol 1996;7:567-572.
26. Modification of Diet in Renal Disease Study Group: Design and statistical issues of the modification of diet in renal disease trial. Control Clin Trials 1991;12:566-586.
27. Hauser AC, Derfler K, Balcke P: Progression of renal insufficiency in analgesic nephropathy: Impact of drug abuse. J Clin Epidemiol 1991; 44:53-56.
28. Anderson S, Rennke HG, Brenner BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986;77:1993-2000.
29. Gansevoort RT, Heeg JE, Vriesendorp R, de Zeeuw D, de Jong PE: Antiproteinuric drugs in patients with idiopathic membranous glomeruIopathy. Nephrol Dial Transplant 1992;7(suppl 1);S91-S96.
30. Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D: Efficacy and variability of the antiproteinuric effect of lisinopril. Kidney Int 1989;36:272-279.
31. Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong PE: The antiproteinuric effect of blood pressure lowering agents: A meta-analysis of comparitive trials. Nephrol Dial Transplant 1995;10:1963-1974.
32. Hannedouche T, Landais P, Goldfarb B, El Esper N, Fournier A, Godin M, Durand D, Chanard J, Mognon F, Suc J-M, Grünfeld J-P: Randomised controlled trial of enalapril and beta-blockers in non-diabetic chronic renal failure. Br Med J 1994;309:833-837.
33. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Motolese M, Ponticelli C, Ritz E, Zuchelli P: Effect of the angiotensin converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996;334:939-945.
34. Kamper AL, Strandgaard S, Leyssac PP: Effect of enalapril on progression of chronic renal failure. Am J Hypertens 1992;5:423-430.
35. Bedogna V, Valvo E, Casagrande P, Braggio P, Fontanarosa C, Dal Santo F, Alberti D, Maschio G: Effects of ACE inhibition in normotensive patients with chronic glomerular disease and normal renal function. Kidney Int 1990; 38:101-107.
36. Gansevoort RT, de Zeeuw D, de Jong PE: Long-term benefits of the antiproteinuric effect of ACE-inhibition in non-diabetic renal disease. Am J Kidney Dis 1993;2:202-206.
37. Gansevoort RT, de Zeeuw D, de Jong PE: Additive antiproteinuric effect of ACE inhibition and a low-protein diet in human renal disease. Nephrol Dial Transplant 1995;10:497-504.
38. Bannister KM, Weaver A, Clarkson AR, Woodroffe AJ: Effect of angiotensin-converting enzyme and calcium channel inhibition on progression of IgA nephropathy. Contrib Nephrol. Basel, Karger, 1995, vol 111, pp 184-193.
39. Zucchelli P, Zuccala A, Gaggi R: Comparison of the effects of ACE inhibitors and calcium channel blockers on the progression of renal failure. Nephrol Dial Transplant 1995; 10(suppl 9):46-51.
40. Praga M, Hernandez E, Montoyo C, Andres A, Ruilope LM, Rodico JL: Long-term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria. Am J Kidney Dis 1992;20:240-248.
41. Liou HH, Huang TP, Campese VM: Effect of long-term therapy with captopril on proteinuria and renal function in patients with non-insulin dependent diabetic and non-diabetic renal disease. Nephron 1995;69:41-48.
42. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G, The Modification of Diet in Renal Disease Study Group: The effects of dietary protein restriction of blood pressure control on the progression of chronic renal disease. N Engl J Med 1994;330: 877-884.
43. Hunt LP, Short CD, Mallick NP: Prognostic indicators in patients presenting with the nephrotic syndrome. Kidney Int 1988;34:382-388.
44. Ideslon BA, Smithlime N, Smith GW, Harrington JT: Prognosis in steroid treated idiopathic nephrotic syndrome. Ann Int Med 1988;137: 891-896.
45. van der Kleij FHG, Navis GJ, Scheffer H, Gansevoort RT, Heeg JE, de Zeeuw D, de Jong PE: ACE-polymorphism does not determine short-term renal response to ACE-inhibition in proteinuric patients. Nephrol Dial Transplant, submitted.
46. Wapstra FH, van Goor H, Navis GJ, de Jong PE, de Zeeuw D: Antiproteinuric effect predicts renal protection by angiotensin-converting enzyme inhibition in rats with established adriamycin nephrosis. Clin Sci 1996;90:393-401.
47. Maki DD, Ma JZ, Louis TA, Kasiske BL: Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Int Med 1995;155:1073-1080.
48. Heeg JE, de Jong PE, Vriesendorp R, de Zeeuw D: Additive antiproteinuric effect of the NSAID indomethacin and the ACE inhibitor lisinopril. Am J Nephrol 1990;10(suppl 1):94-97.